Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

It is most effective at managing blood sugar overnight and between meals. While long-acting insulin is slow to reach the bloodstream and has a relatively low peak, it stabilizes the “plateau ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

Merilog marks the third insulin biosimilar to receive FDA approval, following the greenlight of two long-acting biosimilar insulin products in 2021. Diabetes, a chronic disease impacting more than ...

The FDA previously approved two long-acting insulin biosimilars, Mylan Pharmaceuticals’ Semglee in June 2020 and Lilly’s glargine biosimilar, Rezvoglar in December 2021. Merilog is approved as ...

Crucially, the long-acting insulin was no worse than Tresiba when it came to rates of hypoglycaemia, when blood glucose levels dip too low, according to statistical comparisons between the drugs.

The rapid-acting insulin aspart biosimilar joins two prior long-acting insulin biosimilar products approved in 2021. Biosimilars are highly similar to already approved products and have no ...

With the approval, Merilog joins two other long-acting biosimilar insulin products. Perspective from Irl B. Hirsch, MD, MACP The FDA has approved the first rapid-acting biosimilar insulin product ...

Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA. Approval of biosimilar products can ...

Merilog is available in a 3 mL prefilled pen and a 10 mL vial, joining two long-acting insulin biosimilars approved by the FDA in 2021. Merilog, a rapid-acting human insulin analog, is the first ...